| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.485.961 | 1.568.263 | 1.728.924 | 1.729.786 | 2.395.580 | 2.560.539 | 2.553.024 | 2.945.067 | 3.472.671 | 4.098.445 |
| Total Income - EUR | 1.487.828 | 1.577.143 | 1.742.940 | 1.730.999 | 2.432.037 | 2.575.751 | 2.566.100 | 2.966.016 | 3.568.696 | 4.119.857 |
| Total Expenses - EUR | 1.459.989 | 1.552.634 | 1.703.490 | 1.705.082 | 2.333.886 | 2.441.807 | 2.468.188 | 2.886.720 | 3.490.405 | 4.169.663 |
| Gross Profit/Loss - EUR | 27.839 | 24.509 | 39.450 | 25.917 | 98.151 | 133.943 | 97.912 | 79.296 | 78.292 | -49.807 |
| Net Profit/Loss - EUR | 23.385 | 18.947 | 23.140 | 17.886 | 81.715 | 109.808 | 81.080 | 62.911 | 60.956 | -49.807 |
| Employees | 13 | 14 | 15 | 15 | 28 | 28 | 31 | 31 | 31 | 31 |
Check the financial reports for the company - Neopharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 131.670 | 111.525 | 108.838 | 103.553 | 153.385 | 139.947 | 209.683 | 213.211 | 214.798 | 232.786 |
| Current Assets | 690.351 | 617.361 | 811.298 | 799.192 | 894.209 | 1.025.581 | 899.648 | 1.048.885 | 1.180.413 | 1.332.336 |
| Inventories | 401.530 | 378.568 | 427.868 | 337.179 | 585.925 | 665.803 | 580.049 | 665.859 | 740.490 | 929.207 |
| Receivables | 206.483 | 142.286 | 301.310 | 427.813 | 264.628 | 319.136 | 270.542 | 351.838 | 410.696 | 375.558 |
| Cash | 27.376 | 96.506 | 82.120 | 34.200 | 43.656 | 40.642 | 49.058 | 31.188 | 29.228 | 27.572 |
| Shareholders Funds | 397.968 | 390.589 | 340.442 | 338.840 | 411.889 | 455.096 | 488.838 | 508.121 | 556.801 | 445.804 |
| Social Capital | 89.989 | 89.071 | 87.564 | 85.957 | 107.051 | 105.022 | 102.693 | 103.011 | 102.699 | 102.125 |
| Debts | 424.053 | 338.297 | 579.694 | 563.904 | 626.697 | 703.455 | 615.489 | 750.780 | 837.046 | 1.117.961 |
| Income in Advance | 0 | 0 | 0 | 0 | 9.009 | 6.977 | 5.003 | 3.194 | 1.365 | 1.357 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Neopharm Srl